Xi Cheng

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial

Tingyan Shi, Jianqing Zhu, Yanling Feng et al. · The Lancet Oncology · 2021 · 211 citations

Chemotherapy Versus Chemotherapy, Secondary Cytoreduction, Medicine +7

Surgical treatment for patients with different origins of Krukenberg tumors: Outcomes and prognostic factors

Rong Jiang, Jie Tang, Xi Cheng et al. · European Journal of Surgical Oncology · 2008 · 115 citations

Different Origins, Krukenberg Tumors, Surgical Oncology +7

<i>BRCA1</i> and <i>BRCA2</i> mutations in ovarian cancer patients from China: ethnic‐related mutations in <i>BRCA1</i> associated with an increased risk of ovarian cancer

Tingyan Shi, Pan Wang, Caixia Xie et al. · International Journal of Cancer · 2017 · 61 citations · Full text

Brca1/2 Genetic Testing, Breast Oncology, Cancer Risk +15

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study

Rong Jiang, Sheng Yin, Chao You et al. · BMC Cancer · 2015 · 50 citations · Full text

Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction

Wen‐Juan Tian, Rong Jiang, Xi Cheng et al. · Journal of Surgical Oncology · 2010 · 49 citations